Sarissa Capital Management LP Watch

from SC 13D/A 2 pages Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members Sarissa Believes Amarin Risks Destroying Additional Shareholder Value Unless Sarissa Representatives Are Immediately Added to the Board Amarin Board’s Governance Process Lacks Urgency and Disregards Shareholder Vote at Annual Meeting

from SC 13D/A 1 page Sarissa Capital Comments on Alkermes Annual Meeting Sarissa Concerned That Alkermes Board Is Being Unduly Influenced by CEO Richard Pops Sarissa Supports New Alkermes Directors to Step Up and Act for the Benefit of Shareholders Sarissa Is Considering Taking Action Under Irish Law to Selectively Remove and Replace Alkermes Directors

from SC 13D 23 pages Apricus Biosciences, Inc. 11975 El Camino Real, Suite 300 San Diego, California 92130 Gentlemen: The Undersigned (Collectively, the “Investors”) Hereby Severally Confirm Their Respective Agreements With Apricus Biosciences, Inc., a Nevada Corporation (The “Company”), as Follows: 1. This Subscription Agreement, Including the Terms and Conditions for Purchase of Securities Attached Hereto as Annex I (Collectively, (This “Agreement”), Is Made as of the Date Set Forth Below Between the Company and the Investors

from SC 14D9/A 1 page Sarissa Capital Highlights Advancement of Astex Pipeline Compound